Switzerland is home to a highly innovative life sciences cluster. Many multinational corporations, as well as a network of smaller companies and startups have operations in Switzerland, mostly in the Basel Area. The industry is vibrant, with many innovative developments occurring in pharmaceuticals, biotech or digital health.
In China, the life sciences industry has been growing at an accelerated pace in the last few years and at the same time China is moving towards becoming the largest pharmaceutical market in the world. Both, Swiss and Chinese companies have a lot to gain from innovation and international expansion.
During this year’s Swiss-Chinese Life Sciences Forum, we will address current key issues in the industry. Guest speakers from Swiss as well as Chinese companies will present insights into the following topics:
· Ways to set up operations in Switzerland to access the European market
· Innovation at startups
· Macro-economic trends in the life sciences industry and regulatory developments
· Strengthening Sino-Swiss collaboration
We are looking forward to welcoming you at this year’s Life Sciences Forum!
Please click HERE for registration until March 15, 2022. You will be redirected to our cooperation partner Basel Area.
|09:30||Welcome Remarks by the Swiss-Chinese Chamber of Commerce, VISCHER AG and Basel Area Business & Innovation||B. Wei, General Manager, SCCC | C. Wyss, Partner, Vischer | A. Hollnagel, Director Asia, Basel Area|
|09:35||Introduction of Panelists l||G. Schweizer, Moderator|
|09:40||Cancer has No Borders! BeiGene’s Way from Beijing to Basel and a Global Organization||N. Eckardt, Vice President Medical Affairs Europe, BeiGene|
|09:55||From Europe to China and Back – How WORG Pharmaceutical Leverages the Best of Both Worlds||R. Henning, Chief Scientific Officer & Head of European Operations, Worg Pharm Co. Ltd.|
|10:10||Game Changing Innovation – HK Biorhythm’s Technology and Strategy for Internationalization||J. Liu, CEO, HK Bio Rhythm R&D Company Ltd.|
|10:25||Panel Discussion l|
N. Eckardt | R. Henning | J. Liu
Introduction of Panelists ll
Is the Chinese Biotech Industry Overheated? Macroeconomic Trends in the Life Sciences Industry
P. Jantzer, Senior Managing Director, Accenture
Entering the Chinese pharmaceutical market – requirements for marketing authorization holders
M. Zhan, Senior RA Consultant, Accestra
New Ways of Innovating – What China Expects from Chinese Startups
Q. Tang, Head of Roche Accelerator China, Roche
Panel Discussion ll
P. Jantzer | M. Zhan | Q. Tang
B. Wei | C. Wyss | A. Hollnagel